UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial

European Journal of Cancer

Volumn 37, Issue 13, 2001, Pages 1642-1647

  Ravaud, A ^a   Borner, M ^a,b   Schellens, J H M ^a,c   Geoffrois, L ^a,d   Schoffski B P ^a,e   Kroon, K ^f   Wanders, J ^f   Hanauske, A R ^a,g   Fumoleau, P ^a,h  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITY OF BERN   (Switzerland)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d CENTRE ALEXIS VAUTRIN   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f New Drug Development Office   (Netherlands)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Chemotherapy; Gastric cancer; Leucovorin; Phase II; UFT

Indexed keywords

CARMUSTINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN C; TEGAFUR; UFT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CARCINOMA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 0034885980     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00187-3     Document Type: Article

References (29)

1. Cancer statistics
2. Epidemiologic studies in gastric adenocarcinoma
3. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer
4. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma
5. Treatment of advanced gastric cancer with DDP, (cisplatin), adriamycin, and 5-fluorouracil (DAF)
6. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis
7. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer
8. FAMTX (fluorouracil, methotrexate, adriamycin) is as effective and less toxic than EAP (etoposide, adriamycin, cisplatin): A random assignment trial in gastric cancer
9. New developments in the treatment of gastric carcinoma
10. Sequential high dose methotrexate and fluorouracil combined with doxorubicin - A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group
11. Randomized trial comparing epirubicin, cisplatinum, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
12. Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin and mitomycin (BAFMi) in the treatment of advanced gastric cancer. A phase III trial of the Italian clinical research oncology group (GOIRC)
13. Fluorouracil versus FAM polychemotherapy in gastric cancer. A randomized study
14. Analogs of pyrimidine nucleosides
15. Studies of co-administration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivates
16. Report of nationwide pooled data and cohort investigation in UFT phase II studies
17. Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer
18. Effect of PMUE (CDDP, MMC, UFT, etoposide) for terminal gastric cancer
19. Combination chemotherapy with UFT, etoposide, CDDP, adriamycin (FEPA) in advanced gastric cancer
20. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of ONCOPAZ cooperative group
21. Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma
22. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma
23. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma
24. UFT plus leucovorin (LV) in advanced colorectal cancer (CCR). A phase II trial
25. Randomized comparative study of orzel (oral uracil/tegafur (UFT)) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
26. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer
27. Clinical phase II study of UFT by cooperative study group
28. Clinical trial on the effect of UFT
29. Phase II trial of UFT in advanced colorectal cancer and gastric cancer